Abstract
The existence of stable, transcriptionally silent human immunodeficiency virus (HIV) in latently infected cells represents a major obstacle to acquired immune deficiency syndrome (AIDS) therapy. Histone deacetylase (HDAC) can inhibit histone acetylation, resulting in HIV-1 provirus transcription silence. Apicidin, a widely used antiparasitic drug, exhibits antiparasitic activity by inhibiting HDAC. Using the latently infected A10.6 cell line, we describe the dose- and time-dependent manner in which Apicidin reverses HIV-1 latency. We found that Apicidin can synergize with trichostatin A (TSA) to activate HIV-1 gene expression. Chromatin immunoprecipitation (ChIP) assay further indicates that Apicidin induces HIV-1 reactivation by increasing the acetylation levels of H3 and H4 at nucleosome 1 in HIV-1 long terminal repeats (LTR). Our research reveals a potent activator for reactivating latent HIV-1 and shows promise for HIV-1 therapy.
Keywords: AIDS, apicidin, human immunodeficiency virus type 1, histone acetylation, histone deacetylase inhibitors, latent reservoirs, Cytotoxicity, Cell Culture, Cytometry Analysis, Toxicity Assay
Current HIV Research
Title: HIV-1 Reactivation Induced by Apicidin Involves Histone Modification in Latently Infected Cells
Volume: 9 Issue: 4
Author(s): Shiguan Lin, Yuhao Zhang, Hao Ying and Huanzhang Zhu
Affiliation:
Keywords: AIDS, apicidin, human immunodeficiency virus type 1, histone acetylation, histone deacetylase inhibitors, latent reservoirs, Cytotoxicity, Cell Culture, Cytometry Analysis, Toxicity Assay
Abstract: The existence of stable, transcriptionally silent human immunodeficiency virus (HIV) in latently infected cells represents a major obstacle to acquired immune deficiency syndrome (AIDS) therapy. Histone deacetylase (HDAC) can inhibit histone acetylation, resulting in HIV-1 provirus transcription silence. Apicidin, a widely used antiparasitic drug, exhibits antiparasitic activity by inhibiting HDAC. Using the latently infected A10.6 cell line, we describe the dose- and time-dependent manner in which Apicidin reverses HIV-1 latency. We found that Apicidin can synergize with trichostatin A (TSA) to activate HIV-1 gene expression. Chromatin immunoprecipitation (ChIP) assay further indicates that Apicidin induces HIV-1 reactivation by increasing the acetylation levels of H3 and H4 at nucleosome 1 in HIV-1 long terminal repeats (LTR). Our research reveals a potent activator for reactivating latent HIV-1 and shows promise for HIV-1 therapy.
Export Options
About this article
Cite this article as:
Lin Shiguan, Zhang Yuhao, Ying Hao and Zhu Huanzhang, HIV-1 Reactivation Induced by Apicidin Involves Histone Modification in Latently Infected Cells, Current HIV Research 2011; 9 (4) . https://dx.doi.org/10.2174/157016211796320333
DOI https://dx.doi.org/10.2174/157016211796320333 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Steroid Regulation of Drug-Metabolizing Cytochromes P450
Current Drug Metabolism Histopathological Determinants of Tumor Resistance: A Special Look to the Immunohistochemical Expression of Carbonic Anhydrase IX in Human Cancers
Current Medicinal Chemistry MicroRNA-34a and its target genes: Key factors in cancer multidrug resistance
Current Pharmaceutical Design Epidemiology of Vitamin D and Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Mitochondria: A Promising Target for Anticancer Alkaloids
Current Topics in Medicinal Chemistry Utility of MLH1 Methylation Analysis in the Clinical Evaluation of Lynch Syndrome in Women with Endometrial Cancer
Current Pharmaceutical Design Role of microRNAs in Gynecological Pathology
Current Medicinal Chemistry Role of Progesterone in Human Astrocytomas Growth
Current Topics in Medicinal Chemistry Cytosine Methyltransferases as Tumor Markers
Current Genomics May Endocrine Therapy be Associated with Cognitive Impairment in Breast Cancer Patients?
Clinical Cancer Drugs Prolyl-Specific Peptidases and Their Inhibitors in Biological Processes
Current Chemical Biology An Overview of Bioactive Peptides for in vivo Imaging and Therapy in Human Diseases
Mini-Reviews in Medicinal Chemistry SALL4: Engine of Cell Stemness
Current Gene Therapy Cyclin Dependent Kinase 1 Inhibitors: A Review of Recent Progress
Current Medicinal Chemistry Recent Advances on Liquid Chromatographic and Mass Spectrometric Analysis of Selective Estrogen Receptor Modulators (SERMs) in Biological Fluids
Current Chromatography Mutations of Chromatin Structure Regulating Genes in Human Malignancies
Current Protein & Peptide Science Chemoradiotherapy of Human Tumors: Novel Approaches from Nanomedicine
Current Pharmaceutical Design Pleiotropic Effects of Fenofibrate
Current Pharmaceutical Design Modifications of Cell Signalling and Redox Balance by Targeting Protein Acetylation Using Natural and Engineered Molecules: Implications in Cancer Therapy
Current Topics in Medicinal Chemistry Aspirin as a Chemoprevention Agent for Colorectal Cancer
Current Drug Metabolism